A ketogenic diet, characterized by high fat and low carbohydrates, has gained popularity for its weight-loss benefits and potential protective effects against colon cancer. However, recent research indicates that this dietary approach may not be as universally beneficial as once thought, particularly when it comes to cancer risks in the small intestine.
The study, led by Omer Yilmaz from the MIT Stem Cell Initiative, aimed to explore the effects of a ketogenic diet on the small intestine, building on prior findings that suggested a protective role against colon cancer. Surprisingly, the researchers found that mice adhering to a ketogenic diet exhibited a heightened likelihood of developing tumors in the small intestine compared to those on a standard diet. This increase in tumor formation was linked to the metabolic pathway known as fatty acid oxidation, which becomes more active when the body relies on dietary fat for energy. This pathway triggers signals that prompt stem cells to proliferate more rapidly.
Yilmaz noted the dual nature of stem cell activity; while a greater number of stem cells can enhance the small intestine’s ability to heal, it also raises the risk of tumor development. Although the ketogenic diet was confirmed to suppress colon tumor growth, the researchers concluded that ketone bodies—produced as by-products of fat metabolism—do not play a direct role in this protective effect. Instead, they are seen as metabolic bystanders. This raises questions about the efficacy of commercial ketone supplements, which may have minimal impact on health outcomes. As the team delves deeper into these findings, they aim to unravel why a single dietary approach can yield contrasting effects in different sections of the gastrointestinal tract, underscoring the need for caution in applying generalized statements about dietary impacts on health.
Source: A reason to eat carbs via MIT Technology Review